Tania Gendron, PhD, speaks to the present challenges for translating biomarker discoveries to clinical practice and offers insights to how these can be overcome.
Biomarker exploration has been a crucial component of amyotrophic lateral sclerosis (ALS), explained Tania Gendron, PhD, assistant professor of neuroscience, Mayo Clinic. Data at the individual level has been lacking, Gendron noted, which creates additional challenges in patient care that clinicians and researchers are working to address.
This topic and more, including novel gene therapy research and influential policy, were explored at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference held in Dallas, Texas.
This transcript has been lightly edited; captions were auto-generated.
Transcript
What are some of the significant challenges faced by clinicians looking to translate biomarker discoveries into their clinical practice, and what steps can be taken to overcome these obstacles?
From my perspective as a researcher and those of others, the majority of studies that have been examining newly identified candidate biomarkers do so by evaluating biomarker potential utilities using population cohorts. As an example, multiple studies, including my own, have evaluated use of blood neurofilament and other biomarkers as prognostic biomarkers, meaning a biomarker that predicts disease severity and progression, or as a susceptibility risk biomarker, meaning that it informs impending symptom onset in asymptomatic individuals at genetic risk of ALS. However, biomarker studies comparing population cohorts, as we do, for instance, if you want to compare healthy controls to patients with ALS, those population cohorts provide more robust data at the group level than they do at the individual level. As such, there is a need to validate these biomarkers at the individual level if they are to be in fact, used in clinical practice.
Biomarker measurements and patient fluids are usually a part of using assays or tests. However, one of the challenges here in implementing the biomarker to the clinical practice is that there are large variations in the results when using different tests due to a lack of standard standardization among them. An avenue that is being pursued to overcome this challenge is the development of reference measurement procedures and of certified reference materials that we hope will ensure equivalent results between methods and tests across sites.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More